Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Elena Bartoloni and Roberto Gerli.
Connection Strength

8.971
  1. Hypertension and SARS-CoV-2 infection: is inflammation the missing link? Cardiovasc Res. 2020 11 01; 116(13):e193-e194.
    View in: PubMed
    Score: 0.911
  2. Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. J Clin Med. 2019 Apr 19; 8(4).
    View in: PubMed
    Score: 0.819
  3. Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter? Front Immunol. 2019; 10:817.
    View in: PubMed
    Score: 0.819
  4. Effect of Sinovial High-Low® injections in trapeziometacarpal osteoarthritis. Clin Exp Rheumatol. 2019 Jan-Feb; 37(1):166.
    View in: PubMed
    Score: 0.800
  5. Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality? Front Cardiovasc Med. 2018; 5:177.
    View in: PubMed
    Score: 0.799
  6. The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren's syndrome. Clin Exp Rheumatol. 2018 May-Jun; 36 Suppl 112(3):113-120.
    View in: PubMed
    Score: 0.770
  7. Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nat Rev Cardiol. 2018 Jan; 15(1):33-44.
    View in: PubMed
    Score: 0.730
  8. Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'. Ann Rheum Dis. 2021 Jan 28.
    View in: PubMed
    Score: 0.232
  9. The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience. Front Med (Lausanne). 2020; 7:608728.
    View in: PubMed
    Score: 0.229
  10. Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19. Reumatologia. 2020; 58(5):261-264.
    View in: PubMed
    Score: 0.227
  11. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res. 2020 08; 68(4):213-224.
    View in: PubMed
    Score: 0.224
  12. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol. 2020 Jul-Aug; 38(4):754-759.
    View in: PubMed
    Score: 0.224
  13. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart. Clin Exp Rheumatol. 2020 May-Jun; 38(3):580.
    View in: PubMed
    Score: 0.220
  14. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 07; 111:102468.
    View in: PubMed
    Score: 0.219
  15. The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. Clin Exp Rheumatol. 2019 May-Jun; 37 Suppl 118(3):192-198.
    View in: PubMed
    Score: 0.210
  16. Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjögren's syndrome: a novel pathogenetic scenario? Clin Exp Rheumatol. 2019 May-Jun; 37 Suppl 118(3):133-139.
    View in: PubMed
    Score: 0.210
  17. A Platelet's Guide to Synovitis. Isr Med Assoc J. 2019 Jul; 21(7):454-459.
    View in: PubMed
    Score: 0.208
  18. Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. Clin Exp Rheumatol. 2018 May-Jun; 36 Suppl 112(3):210-214.
    View in: PubMed
    Score: 0.195
  19. Novel Therapeutic Strategies in Primary Sjögren's Syndrome. Isr Med Assoc J. 2017 Sep; 19(9):576-580.
    View in: PubMed
    Score: 0.183
  20. Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. Clin Exp Rheumatol. 2018 May-Jun; 36 Suppl 112(3):73-79.
    View in: PubMed
    Score: 0.181
  21. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmun Rev. 2017 Mar; 16(3):253-257.
    View in: PubMed
    Score: 0.176
  22. Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. Microorganisms. 2021 Jan 07; 9(1).
    View in: PubMed
    Score: 0.058
  23. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clin Exp Rheumatol. 2019 May-Jun; 37 Suppl 118(3):97-106.
    View in: PubMed
    Score: 0.052
  24. Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Front Pharmacol. 2019; 10:296.
    View in: PubMed
    Score: 0.051
  25. Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis. Thromb Haemost. 2017 11; 117(11):2116-2124.
    View in: PubMed
    Score: 0.047
  26. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Front Pharmacol. 2017; 8:369.
    View in: PubMed
    Score: 0.045
  27. Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor? Front Immunol. 2017; 8:554.
    View in: PubMed
    Score: 0.045
  28. Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. J Rheumatol. 2017 08; 44(8):1179-1183.
    View in: PubMed
    Score: 0.045
  29. Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren's syndrome. Clin Exp Rheumatol. 2017 May-Jun; 35(3):546-547.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.